Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 5/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484095 | 1.00 | PNMT (0.46) | PNMTSCN9ACES2TACR1IDO1 | |
| SCHEMBL459815 | 1.00 | PNMT (0.46) | PNMTSCN9ACES2TACR1IDO1 | |
| SCHEMBL29256555 | 0.88 | PNMT (0.41) | PNMTSCN9ACES2PDE2AGRIN2B | |
| SCHEMBL30988810 | 0.88 | PNMT (0.41) | PNMTSCN9ACES2PDE2AGRIN2B | |
| SCHEMBL29256557 | 0.88 | PNMT (0.41) | PNMTSCN9ACES2PDE2AGRIN2B | |
| SCHEMBL25920947 | 0.84 | PNMT (0.47) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL2394599 | 0.81 | PDE2A (0.51) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL7787286 | 0.81 | PNMT (0.49) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL5610427 | 0.81 | PDE2A (0.51) | PNMTCES2TACR1IDO1PDE2A | |
| SCHEMBL531699 | 0.81 | PNMT (0.68) | PNMTCES2TACR1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340754-A | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-8133994-B2 | Preparation of aprepitant | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-03-13 | — | — | US | disclosed |
| US-20110094321-A1 | PREPARATION OF APREPITANT | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-04-28 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-6953792-B2 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-04 | — | — | US | disclosed |
| EP-1286978-A1 | CYCLOHEXYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087866-A1 | CYCLOHEXYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110094321-A1 | PREPARATION OF APREPITANT | KIT, CPA3, CMA1 | PNMT 495/4885SCN9A 1568/4885CES2 2071/4885 |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | CNR2, CNR1, HRH2 | PNMT 1093/4885SCN9A 1683/4885CES2 1566/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PNMT 3212/4885SCN9A 1144/4885CES2 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.